Drug Profile

ID 11902

Alternative Names: ID-11902

Latest Information Update: 22 Jan 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ildong Pharmaceutical
Class Antineoplastics; Small molecules
Mechanism of Action Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Discontinued Solid tumours

Most Recent Events

13 Dec 2022 Discontinued - Preclinical for Solid tumours in South Korea (unspecified route) Prior to December 2022 (Ildong Pharmaceutical pipeline, December 2022)
06 Sep 2022 Ildong Pharmaceuticals plans to files an IND application for a phase I trial in solid tumours in Q1 of 2023
16 May 2022 Ildong Pharmaceuticals files for multiple worldwide patent protection for ID 11902

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com